Ehrig, Lukas
Wagner, Ann-Christin
Wolter, Heike
Correll, Christoph U.
Geisel, Olga
Konigorski, Stefan https://orcid.org/0000-0002-9966-6819
Article History
Received: 13 September 2022
Accepted: 26 June 2023
First Online: 19 July 2023
Competing interests
: C.U.C. has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Damitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. O.G. received honoraria from Takeda and Novartis. C.U.C. and O.G. declare no competing non-financial interests. The remaining authors declare no competing financial or non-financial interests.
: This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice and approved by the local ethics committee at Charité – Universitätsmedizin Berlin (EA2/053/20). Consent/assent requirements were waived for this retrospective chart review study.